Blasco Benjamin, Leroy Didier, Fidock David A
Medicines for Malaria Venture, Geneva, Switzerland.
Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
21世纪初基于青蒿素的联合疗法（ACTs）在全球范围内的采用开创了有效治疗耐药恶性疟原虫疟疾的新纪元。然而，现在几个东南亚国家报告称出现了对青蒿素（ART）衍生物和ACT联合用药敏感性降低的寄生虫，导致治疗失败率不断上升。在此，我们回顾了在理解抗疟药物的作用方式以及耐药性如何产生方面的最新进展，并讨论了有效对抗耐药性、优化治疗以及推进全球疟疾消除运动的新策略。
